HROW
HARROW, INC.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$32.76
−0.97%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11Sep 16Sep 21
Key dataSep 21, 2026
Open$33.00
From 52W high−40.22%
Volume37042.00
Market cap$1.23B
P/E (TTM)—
P/S (TTM)4.5x
Div yield—
Key dataSep 21, 2026
Open
$33.00
From 52W high
−40.22%
Volume
37042.00
Market cap
$1.23B
ValuationView details →
P/E (Fwd)
25.5x
EV/EBITDA
322.2x
P/E (TTM)
—
RSI (14)
28.4
MomentumView details →
1D Return
−0.97%
YTD Return
−34.18%
SummaryUpdated Jun 1, 2026
Harrow Health, Inc. (NASDAQ:HROW) is a specialty pharmaceutical company focused on the ophthalmology market. Originally incorporated in 2006 as Imprimis Pharmaceuticals, the company rebranded to Harrow Health in December 2018 to reflect its broader healthcare focus. Based in San Diego, California, Harrow has evolved from a compounding pharmacy business into a diversified ophthalmic pharmaceutical company that develops, manufactures, and commercializes prescription drugs for eye care professionals and their patients across North America.
Similar companies
Latest newsMore news →
Harrow, Inc. announced that Randall E. Pollard departed as Chief Accounting Officer and principal accounting officer, effective September 4, 2026, and appointed Andrew R. Boll as principal accounting officer, effective the same date.17d agoHarrow Inc. announced clinical study results showing its product Iheezo reduces eye-injection discomfort by more than half.31d agoHarrow reported a Q2 2026 loss of $0.34 per share, missing the Zacks Consensus Estimate of a loss of $0.23, and compared to earnings of $0.24 per share a year ago.42d ago